EFFECT OF TZD ON RESIDUAL BETA CELL FUNCTION IN IDDM

TZD 对 IDDM 中残余 β 细胞功能的影响

• 批准号: 7375332
• 负责人: T HASTINGS WILSON
• 金额: $ 0.12万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375332
• 关键词: EFFECT; TZD; RESIDUAL; BETA; CELL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will determine the effect of Pioglitazone on insulin requirements and control of diabetes in patients with newly diagnosed type 1 diabetes. Pioglitazone is an approved drug for the treatment of type 2 (non-insulin dependent) diabetes in adults. Pioglitazone enhances the action of insulin therapy in patients with type 2 diabetes mellitus. Studies have shown that Pioglitazone also affects immune cells although in much bigger doses. In an animal model of type 1 diabetes, pioglitazone delays the onset or prevents the development of diabetes.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究将确定吡格列酮对新诊断的1型糖尿病患者胰岛素需求和糖尿病控制的影响。吡格列酮是一种批准用于治疗成人2型（非胰岛素依赖型）糖尿病的药物。吡格列酮增强2型糖尿病患者胰岛素治疗的作用。研究表明，吡格列酮也会影响免疫细胞，尽管剂量要大得多。在1型糖尿病的动物模型中，吡格列酮延迟糖尿病的发作或预防糖尿病的发展。